Sugi Predict

Sugi Predict / Compounds / SCHEMBL828674

SCHEMBL828674

SCHEMBL828674

CC(C)(C)OC(=O)NC(COCc1ccccc1)C(=O)O

nearest known ligand 0.90

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 5/20 0.90
▸ PPARG P37231 4/20 0.82
▸ CTSS P25774 3/20 0.72
▸ KLK7 P49862 2/20 0.60
▸ KLK5 Q9Y337 2/20 0.60
▸ ACE P12821 1/20 0.58
▸ FOLH1 Q04609 1/20 0.57
▸ PTPN1 P18031 4/20 0.55
▸ CDC25B P30305 4/20 0.55
▸ PTPN2 P17706 3/20 0.55
▸ CDC25A P30304 2/20 0.55
▸ PTPN6 P29350 1/20 0.55
▸ PTPN11 Q06124 1/20 0.55
▸ RAB9A P51151 1/20 0.55
▸ CTSL P07711 1/20 0.54
▸ CTSB P07858 1/20 0.54
▸ CTSK P43235 1/20 0.54
▸ PPARD Q03181 2/20 0.54
▸ MME P08473 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1132901 1.00 PPARA (0.90) PPARAPPARGCTSSKLK7KLK5
SCHEMBL17051 1.00 PPARA (0.90) PPARAPPARGCTSSKLK7KLK5
SCHEMBL20899650 0.95 PPARA (0.82) PPARAPPARGCTSSKLK7KLK5
SCHEMBL12130757 0.94 PPARA (0.85) PPARAPPARGCTSSKLK7KLK5
SCHEMBL18555201 0.92 PPARA (0.78) PPARAPPARGCTSSKLK7KLK5
SCHEMBL18555200 0.92 PPARA (0.78) PPARAPPARGCTSSKLK7KLK5
SCHEMBL3820032 0.91 PPARA (0.76) PPARAPPARGCTSSKLK7KLK5
SCHEMBL29229102 0.91 PPARA (0.76) PPARAPPARGCTSSKLK7KLK5
SCHEMBL7057256 0.91 PPARA (0.76) PPARAPPARGCTSSKLK7KLK5
SCHEMBL29556874 0.90 PPARA (0.75) PPARAPPARGCTSSKLK7KLK5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 360 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-61010598-A — — None — — JP disclosed
JP-60161999-A — — None — — JP disclosed
EP-4159727-B1 INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN MORPHIC THERAPEUTIC INC (US) 2026-04-08 — — EP disclosed
US-20260091024-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE BIOHAVEN THERAPEUTICS LTD (US) 2026-04-02 — — US disclosed
US-20260070896-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2026-03-12 — — US disclosed
US-20260041673-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE BIOHAVEN THERAPEUTICS LTD (US) 2026-02-12 — — US disclosed
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PEPTIDREAM INC (JP) 2026-01-15 — — US disclosed
US-12472165-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (VG) 2025-11-18 — — US disclosed
US-20250332148-A1 RILUZOLE PRODRUGS AND THEIR USE BIOHAVEN THERAPEUTICS LTD (US) 2025-10-30 — — US disclosed
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS PRETZEL THERAPEUTICS, INC. (US) 2025-10-16 — — US disclosed
WO-1990002138-A1 DEPROTECTION OF PROTECTED PEPTIDES THE ROCKEFELLER UNIVERSITY (US) 1990-03-08 — — WO disclosed
US-4734400-A BRONCHODILATION WITHOUT CARDIOVASCULAR SIDE EFFECTS HOFFMANN-LA ROCHE INC. (US) 1988-03-29 — — US disclosed
EP-0226513-A1 Peptides capable of inhibiting interactions between antigens and lymphocytes T4, products derived therefrom and their applications INSTITUT PASTEUR (FR) 1987-06-24 — — EP disclosed
WO-1987003601-A1 PEPTIDES CAPABLE OF INHIBITING THE INTERACTIONS BETWEEN ANTIGENS AND LYMPHOCYTES T4, PRODUCTS DERIVED THEREFROM AND APPLICATION THEREOF INSTITUT PASTEUR (FR) 1987-06-18 — — WO disclosed
US-4605641-A BRONCHODILATOR AGENTS HOFFMANN-LA ROCHE INC. (US) 1986-08-12 — — US disclosed
JP-S6110598-A PEPTIDE COMPOUND CHEMO SERO THERAPEUT RES INST 1986-01-18 — — JP disclosed
JP-S60161999-A PEPTIDE CHEMO SERO THERAPEUT RES INST 1985-08-23 — — JP disclosed
US-4301045-A RESIN PEPTIDES ARMOUR PHARMACEUTICAL COMPANY (US) 1981-11-17 — — US disclosed
US-4133805-A INHIBIT RELEASE OR PITUITARY GROWTH HORMONE, GLUCAGON, AND INSULIN AMERICAN HOME PRODUCTS CORPORATION (US) 1979-01-09 — — US disclosed
US-3953416-A Synthetic decapeptide having the activity of the luteinizing hormone releasing hormone and method for manufacturing the same FOLKERS KARL 1976-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250320234-A1 LONP1 INHIBITOR COMPOUNDS, USES AND METHODS LONP1, NLN, ACAT1 PPARA 2100/4885PPARG 1869/4885CTSS 871/4885
US-20260091024-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE IL6ST, GFRA3, GFRA1 PPARA 4425/4885PPARG 4266/4885CTSS 1265/4885
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF NSUN3, BCAT1, SLC43A1 PPARA 2794/4885PPARG 3131/4885CTSS 4022/4885
US-20260041673-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE GFRA3, IL6ST, GFRA1 PPARA 4461/4885PPARG 4310/4885CTSS 1454/4885
US-12472165-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 PPARA 4317/4885PPARG 4202/4885CTSS 653/4885
US-20250332148-A1 RILUZOLE PRODRUGS AND THEIR USE APEH, ALDH1A2, UGT1A9 PPARA 4317/4885PPARG 4202/4885CTSS 653/4885
US-20260070896-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS TRPM6, TRPV3, TRPM2 PPARA 1531/4885PPARG 981/4885CTSS 2336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.